Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,938 | 2,145 | 03.10. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.09. | CROSSJECT presents its financial results and key highlights for the first half of 2025 | 143 | GlobeNewswire (Europe) | Press release CROSSJECT presents its financial results and key highlights for the first half of 2025 Cash position: €6.3 million, compared to €7.0 million as of December 31 2024, demonstrating the... ► Artikel lesen | |
22.09. | CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE (ZENEO Midazolam) | 65 | GlobeNewswire (Europe) | Press release CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) DIJON, France - September 22, 2025 (7.30 AM... ► Artikel lesen | |
04.08. | CROSSJECT remains engaged during the summer break | 5 | GlobeNewswire (USA) | ||
24.06. | CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause | 6 | GlobeNewswire (USA) | ||
11.06. | CROSSJECT advances on the development of ZEPIZURE Junior, its solution for epilepsy crises in children | 142 | GlobeNewswire (Europe) | Press release CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children Announces the effective calibration of ZENEO® for the use of ZEPIZURE® in the... ► Artikel lesen | |
04.06. | CROSSJECT: Launch of a capital increase with preferential subscription rights for nearly 5 million euros | 1 | GlobeNewswire (USA) | ||
03.06. | Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 | 95 | GlobeNewswire (Europe) | Press release Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 Dijon, France 03 June 2025 (07.30 CET) -- CROSSJECT (ISIN: FR0011716265... ► Artikel lesen | |
CROSSJECT Aktie jetzt für 0€ handeln | |||||
27.05. | CROSSJECT implements new manufacturing module to scale-up the ZENEO Factory 's versatility and capacity in anticipation of full product pipeline deployment | 3 | GlobeNewswire (USA) | ||
20.05. | CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval | 2 | GlobeNewswire (USA) | ||
15.05. | CROSSJECT's ZENEO needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors | 156 | GlobeNewswire (Europe) | Press Release CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors... ► Artikel lesen | |
07.05. | CROSSJECT provides updates on the EUA filing of ZEPIZURE | 2 | GlobeNewswire (USA) | ||
27.03. | CROSSJECT reports financial results for 2024 | 222 | GlobeNewswire (Europe) | Press Release CROSSJECT reports financial results for 2024 Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer... ► Artikel lesen | |
25.03. | CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO adrenal insufficiency program | 265 | GlobeNewswire (Europe) | Press Release CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program CROSSJECT enhanced its collaboration with Eton Pharmaceuticals,... ► Artikel lesen | |
12.02. | Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board | 220 | GlobeNewswire (Europe) | Dijon, FRANCE, February 12, 2025 - 0730 (CET) - Crossject (ISIN: FR0011716265; Euronext Growth: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free... ► Artikel lesen | |
19.12.24 | Crossject confirms ZEPIZURE supply chain readiness with another successful ISO audit for Quality Management System | 187 | GlobeNewswire (Europe) | Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S. Dijon, France, December 19, 2024... ► Artikel lesen | |
22.10.24 | Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE ahead of filing U.S. Emergency Use Authorization | 194 | GlobeNewswire (Europe) | Product batch announced in July yielded new regulatory stability data. These results will directly support the requested 6-month stability data in the first quarter of 2025Crossject expects to file... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 47,160 | +0,32 % | ROUNDUP/Aktien Frankfurt Schluss: Dax setzt wieder zurück - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen am Vortag hat der Dax am Donnerstag wieder den Rückwärtsgang eingelegt. Als Belastung für die hiesigen Börsen erwiesen sich zeitweise vor allem die... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 47,640 | +1,56 % | DAX: Warten auf Impulse - SAP, BASF, Siemens Healthineers, Evonik und Rational im Fokus | Auch am letzten Handelstag der Woche fehlen dem deutschen Leitindex größere Impulse, nachdem die wichtigsten US-Börsen am Donnerstag leicht im Minus geschlossen haben. Im frühen Handel wird der DAX... ► Artikel lesen | |
INTUITIVE SURGICAL | 388,25 | +0,37 % | Opening Bell: Puma, Novo Nordisk, Droneshield, Rio Tinto, Robinhood, Intuitive Surgical | Alle Jahre wieder droht in den USA der Regierungsshutdown. Auch dieses Jahr. Demokraten und Republikaner haben sich noch nicht auf einen Haushalt geeinigt. Auswirkungen an der Börse waren noch nicht... ► Artikel lesen | |
SERNOVA BIOTHERAPEUTICS | 0,115 | 0,00 % | Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused... ► Artikel lesen | |
FAMICORD | 6,000 | +1,69 % | EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. erwirbt 100 % der Anteile an der Stammzellbank 'nOvum' spólka z ograniczona odpowiedzialnoscia, Warschau, Polen | EQS-Ad-hoc: FamiCord AG / Schlagwort(e): Fusionen & Übernahmen
FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. erwirbt 100 % der Anteile an der Stammzellbank 'nOvum' spólka z ograniczona... ► Artikel lesen | |
GERATHERM MEDICAL | 5,520 | -0,72 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
ALIGN TECHNOLOGY | 114,20 | +0,62 % | Earnings Preview: What To Expect From Align Technology's Report | ||
NUGEN MEDICAL DEVICES | 0,033 | +4,38 % | Beaking News: NuGen Medical überwindet die "Master-Hürde"! | ||
PLUS THERAPEUTICS | 0,728 | +6,65 % | Plus Therapeutics Inc.: Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer | HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed... ► Artikel lesen | |
CARDINAL HEALTH | 133,20 | -0,11 % | Dividendenbekanntmachungen (01.10.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACRES COMMERCIAL REALTY CORP PFD D US00489Q3002 0,4921 USD 0,4193 EUR AECOM US00766T1007 0,26 USD 0,2215 EUR AFRICAN RAINBOW MINERALS... ► Artikel lesen | |
RESMED | 237,90 | +0,38 % | RESMED INC: Statement of CDIs on issue - RMD | ||
DAVITA | 112,40 | -0,22 % | Aktienmarkt: DaVita-Aktie tritt auf der Stelle (110,9548 €) | Wenig Kursbewegung zur Stunde bei der Aktie von DaVita . Das Wertpapier notiert derzeit bei 130,14 US-Dollar. Der Kurs der Aktie von DaVita zeigt sich aktuell kaum verändert im Vergleich zu der Schlussnotierung... ► Artikel lesen | |
MEDICLIN | 3,220 | 0,00 % | EQS-News: MEDICLIN AG: MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025
31.07.2025 / 13:13 CET/CEST
Für... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,850 | +0,71 % | Atossa Therapeutics appoints Janet Rea as SVP of R&D | ||
BRIGHTSPRING HEALTH SERVICES | 28,360 | -1,36 % | BrightSpring Health Services, Inc. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Guidance | LOUISVILLE, Ky., May 02, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen |